Redundancies in CDRD and PBAC roles in continuous dispute
By Lee, Hye-Kyung | translator Alice Kang
21.10.31 06:32:50
가나다라
0
Took 4 years for new anticancer drugs to pass the first step to expand its reimbursement standards
The fairness of the system also rises as in issue with a committee member who participated in a clinical trial of a competitor’s drug participating in the reimbursement review meeting
[News follow-up from a friendly reporter]
The functional redundancies in the Cancer Disease Review Committee (CDRC) and Pharmaceutical Benefit Appraisal Committee (PBAC) arose as an issue at the NA Health and Welfare Committee audit recently. At the audit, the National Assembly Health and Welfare Committee member Sun-woo Kang of the Democratic Party of Korea had pointed out that a long-term delay has occurred in discussions on expanding reimbursement for a new anti-cancer drug due to the redundant functions of the two committees.
The new anti-cancer drug that Kang referred to was MSD Korea’s ‘Keytruda (pembrolizumab).’ ‘Keytruda is an immu
Lee, Hye-Kyung(hgrace7@dailypharm.com)
If you want to see the full article, please JOIN US (click)